This session surveys the expanding therapeutic landscape in alcohol-associated liver disease across the translational spectrum. Presentations span phase 2 trial data on incretin-based agents (zalfermin, cagrilintide, semaglutide) and target trial emulation of GLP-1 receptor agonists in decompensated cirrhosis, alongside preclinical studies of the repurposed PDE4 inhibitor roflumilast and examination of Rifaximin's potential to impact the microbiome to reduce fibrosis progression in ALD. Additional talks examine pharmacologic management of alcohol use disorder and its downstream hepatic impact, and the effect of alcohol-associated hepatitis on terlipressin response in hepatorenal syndrome. Through early-phase and preclinical work, animal models, and exploratory and retrospective analyses, these studies highlight both novel and repurposed agents and the evolving evidence base guiding their potential clinical application.

This session explores the cellular and molecular drivers of cholestatic liver disease and emerging therapeutic strategies utilizing biliary gene therapy. Presentations examine the impact of impairments in biliary transport and signaling in promoting cholestatic injury, inflammation, and fibrosis.

This session presents genomic and molecular discoveries in liver disease, spanning cirrhosis risk loci, single-cell/spatial transcriptomics in hepatoblastoma, and population-scale genetic variant studies in MASLD and HCC.

The management of chronic liver disease is rapidly evolving from static assessments of fibrosis toward a more comprehensive, precision-based approach that incorporates advanced imaging, noninvasive biomarkers, and emerging therapeutic strategies. Across diverse etiologies—including MASLD, MetALD, alcohol-associated liver disease, cured hepatitis C, and cirrhosis—novel tools are improving clinicians' ability to predict decompensation, identify clinically significant portal hypertension, and personalize treatment decisions. This session will highlight innovative approaches that combine liver stiffness measurements with clinical risk scores, introduce simplified point-of-care strategies for diagnosing portal hypertension, and examine the impact of commonly used metabolic therapies such as statins and SGLT2 inhibitors on liver-related outcomes. In addition, speakers will explore the growing recognition of extrahepatic manifestations of cirrhosis, including the relationship between autonomic dysfunction, sleep physiology, and cognitive impairment.

The treatment landscape for portal hypertension complications continues to expand beyond traditional therapies. Advances in pharmacologic management, refinements in TIPS technology, and novel approaches to ascites, encephalopathy, and decompensation prevention are reshaping patient care. This session will present cutting-edge clinical trials evaluating established and emerging therapies and examine how disease-modifying interventions may alter the natural history of cirrhosis.

This session on the MASH  clinical trial pipeline explores the rapid evolution of drug development.  It covers emerging molecules in the pipeline, mechanisms of action, and late-stage trial endpoints addressing fibrosis and cirrhosis.

This session will examine evolving therapeutic approaches for metabolic dysfunction-associated steatohepatitis, with emphasis on pharmacologic and mechanistic interventions targeting steatohepatitis, fibrosis, metabolic dysfunction, and cirrhosis. Together, these studies showcase the expanding treatment landscape for MASH across disease stages, fibrosis severity, cardiometabolic subgroups, and emerging therapeutic mechanisms.

a { text-decoration: none; color: #464feb; } tr th, tr td { border: 1px solid #e6e6e6; } tr th { background-color: #f5f5f5; }

This session highlights emerging advances in pediatric hepatology, spanning gene-editing therapies, cancer biology, immune-mediated liver injury, transplant-related complications, and innovative biomarker approaches. Presentations showcase translational research and clinical studies that are advancing precision diagnosis, prognostication, and treatment of pediatric liver diseases.

This session highlights advances in expanding and optimizing the donor organ pool through machine perfusion, refined donor selection, and improved risk prediction. Presentations span the transplant pathway—from DCD procurement decisions and normothermic machine perfusion strategies to graft-threatening complications and downstaging protocols for HCC—with an emphasis on interpretable modeling and translational interventions. Together, these studies point toward safer, broader organ utilization and better post-transplant outcomes.

Nicole Kim, MD, MPH is an Assistant Professor of Medicine within the Division of Gastroenterology and Hepatology at the University of Washington. Dr. Kim has a research interest in improving clinical outcomes in liver disease and promoting the early detection of liver cancer through timely receipt of screening.